Figure 2.

(A) Schematic representation of the in vivo injection protocol used. Imnunoliposomes containing MAb against Aβ peptide (B), or the same MAb alone (C), or control IgG (D) were injected following the procedure indicated. Schematic representation of how MAb against Aβ peptide may imbalance the Aβ peptide equilibrium from the brain to blood through blood-brain barrier (BBB). Our data indicated that Lip-MAb reduces the presence of amyloid inside the brain better than the same MAb alone, or irrelevant mouse IgG. Immunofluorescence analysis of mouse brain sections. Brain coronal fixed sections from mice treated with and Lip-MAb (B), MAb (C), or with non-specific IgG (D), were stained with 6E10 antibody (red) and an anti-glial fibrillary acidic protein (GFAP) antibody (green). Note that these images correspond with representative sections similar to those contained in the manuscript (Ordóñez-Gutiérrez et al., 2017).